Form 4: Skye Bioscience Director, Karen L. Smith, Acquires Stock Options

Karen L. Smith, a director of Skye Bioscience, Inc., reports the acquisition of stock options exercisable for 35,000 shares of common stock.

Summary

• On February 24, 2025, Karen L. Smith, a director of Skye Bioscience, Inc., acquired stock options.
• These options grant the right to purchase 35,000 shares of Skye Bioscience common stock at an exercise price of $2.89 per share.
• The options vest in equal monthly installments over one year, starting February 21, 2025, and expire on February 25, 2035.
• Following this transaction, Ms. Smith directly owns 35,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The director's acquisition could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates